Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis, March 2013
According to this report, the global oncology drugs industry experienced significant growth during the past five years and is expected to continue that momentum to reach an estimated $100.6 billion in 2018.
The global oncology drugs industry experienced significant growth during the past five years and is expected to continue that momentum to reach an estimated $100.6 billion in 2018.
Lucintel, a leading global management consulting and market research firm, has analyzed the global oncology drugs industry and presents its findings in Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis. The industry comprises firms primarily engaged in the development, manufacture, and marketing of oncology drugs.
Lucintels study of the oncology drugs industry includes all classes of drugs that are used as an anti-cancer drug for the treatment of cancer such as lung cancer, mouth cancer, colorectal cancer, skin cancer, kidney cancer, and all such other types of cancer, which are marketed and distributed as an oncology drugs.
North America dominates this industry with more than one-third of the market share. Roche Holding Ltd., Novartis AG, Astra Zeneca Plc, Eli Lilly & Co., and Sanofi SA are the major industry players. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly. The industry has seen a number of recent changes including growing competition, rise in merger and acquisition activities, increased cancer health insurance coverage, and an increasing amount of foreign direct investment.
As per the study, aging population, changing lifestyles, more effective diagnosing, unhealthy eating habits, and an increasing incidence of chronic diseases across the entire global population will provide growth opportunities for the oncology drugs industry players.
This study provides an overview of the global oncology drugs industry and tracks industry performance in four geographic regions. The report studies manufacturers and distributors of oncology drugs, providing a five-year annual trend analysis that highlights market size, profit and cost structure for North America, Europe, Asia Pacific (APAC), and the Rest of the World (ROW). The report also provides a forecast, addressing market opportunities for next five years for each of these regions.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the markets potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global oncology drugs industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of this market report are:
The global oncology drugs industry experienced significant growth during the past five years and is expected to continue that momentum to reach an estimated $100.6 billion in 2018.
Lucintel, a leading global management consulting and market research firm, has analyzed the global oncology drugs industry and presents its findings in Global Oncology Drugs Industry 2013-2018: Trend, Profit, and Forecast Analysis. The industry comprises firms primarily engaged in the development, manufacture, and marketing of oncology drugs.
Lucintels study of the oncology drugs industry includes all classes of drugs that are used as an anti-cancer drug for the treatment of cancer such as lung cancer, mouth cancer, colorectal cancer, skin cancer, kidney cancer, and all such other types of cancer, which are marketed and distributed as an oncology drugs.
North America dominates this industry with more than one-third of the market share. Roche Holding Ltd., Novartis AG, Astra Zeneca Plc, Eli Lilly & Co., and Sanofi SA are the major industry players. A combination of factors such as technology innovations, medical insurance coverage, aging population, and changing lifestyles are seen to affect market dynamics significantly. The industry has seen a number of recent changes including growing competition, rise in merger and acquisition activities, increased cancer health insurance coverage, and an increasing amount of foreign direct investment.
As per the study, aging population, changing lifestyles, more effective diagnosing, unhealthy eating habits, and an increasing incidence of chronic diseases across the entire global population will provide growth opportunities for the oncology drugs industry players.
This study provides an overview of the global oncology drugs industry and tracks industry performance in four geographic regions. The report studies manufacturers and distributors of oncology drugs, providing a five-year annual trend analysis that highlights market size, profit and cost structure for North America, Europe, Asia Pacific (APAC), and the Rest of the World (ROW). The report also provides a forecast, addressing market opportunities for next five years for each of these regions.
This comprehensive guide from Lucintel provides readers with valuable information and the tools needed to successfully drive critical business decisions with a thorough understanding of the markets potential. This report will save Lucintel clients hundreds of hours in personal research time on a global market and it offers significant benefits in expanding business opportunities throughout the global oncology drugs industry analysis. In a fast-paced ever-changing world, business leaders need every advantage available to them in a timely manner to drive change in the market and to stay ahead of their competition. This report provides business leaders with a keen advantage in this regard by making them aware of emerging trends and demand requirements on an annual basis.
To make any investment or strategic decision, you need adequate and timely information. This market report fulfills this core need. Some of the features of this market report are:
- Industry size estimates in terms of (US $) value by regions
- Global oncology drugs industry analysis annual trend (2007-2012) and forecast (2013-2018)
- Porters Five Force analysis
- New product launch and merger and acquisition activity in global oncology drugs industry analysis
- Quarterly demand trend (Q1 2011-Q4 2012) and forecast analysis (Q1 2013-Q4 2014) for global oncology drugs industry analysis
- Gross and net profit trends in the global oncology drugs industry analysis
- Cost structure trend in the global as well as regional oncology drugs analysis
- More than 48 valuable figures/charts and 12 tables are provided in this report
1. EXECUTIVE SUMMARY
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6. INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
2. INDUSTRY DEFINITION AND SCOPE
3. INDUSTRY OVERVIEW
4. GLOBAL MACROECONOMIC OVERVIEW
5. INDUSTRY TRENDS
6. INDUSTRY FORECASTS
7. EMERGING TRENDS
8. CONCLUSIONS
LIST OF FIGURES
CHAPTER 3. INDUSTRY OVERVIEW
Figure 3.1: External forces shaping global oncology drugs industry
CHAPTER 4. GLOBAL MACROECONOMIC OVERVIEW
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
CHAPTER 5. INDUSTRY TRENDS
Figure 5.1: Global oncology drugs industry annual trend 2007-12 (US $B)
Figure 5.2: Global oncology drugs industry regional trend 2007-12 (US $B)
Figure 5.3: Global oncology drugs industry regional trend 2007-12 (%)
Figure 5.4: Global oncology drugs industry segment trend 2007-12 (US $B)
Figure 5.5: Global oncology drugs industry segment trend 2007-12 (%)
Figure 5.6: Global oncology drugs industry quarterly trend 2010-11 (US $B)
Figure 5.7: Global oncology drugs industry profitability trend 2007-12
Figure 5.8: Global oncology drugs industry revenue per employee trend 2007-12
Figure 5.9: Cost structure of global oncology drugs industry 2007-12
Figure 5.10: Cost structure in North American oncology drugs industry 2007-12
Figure 5.11: Cost structure in European oncology drugs industry 2007-12
Figure 5.12: Cost structure in Asia Pacific oncology drugs industry 2007-12
Figure 5.13: Top 5 companies vs. oncology drugs industry gross profit & net profit analysis 2012
Figure 5.14: Cash on hand for global oncology drugs industry 2007-12 (US $B)
Figure 5.15: Cash on hand for global oncology drugs industry 2007-12 (%)
Figure 5.16: Asset for global oncology drugs industry 2007-12 (US $B)
Figure 5.17: Assets for global oncology drugs industry 2007-12 (%)
Figure 5.18: Debt for global oncology drugs industry 2007-12 (US $B)
Figure 5.19: Debt for global oncology drugs industry 2007-12 (%)
Figure 5.20: Industry shares of top players in global oncology drugs industry in 2007
Figure 5.21: Industry shares of top players in global oncology drugs industry in 2012
Figure 5.22: Global oncology drugs industry 2007 market share analysis
Figure 5.23: Global oncology drugs industry 2012 market share analysis
CHAPTER 6. INDUSTRY FORECASTS
Figure 6.1: Global oncology drugs industry annual forecast 2013-18 (US $B)
Figure 6.2: Global oncology drugs industry quarterly forecast 2013-14 (US $B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global oncology drugs industry regional forecast 2013-18 (US $B)
Figure 6.12: Global oncology drugs industry regional forecast 2013-18 (%)
Figure 6.13: Global oncology drugs industry segment forecast 2013-18 (US $B)
Figure 6.14: Global oncology drugs industry segment forecast 2013-18 (%)
CHAPTER 7. EMERGING TRENDS
Figure 7.1: Global oncology drugs industry opportunity by region
Figure 7.2: Global oncology drugs industry opportunity by segment
CHAPTER 3. INDUSTRY OVERVIEW
Figure 3.1: External forces shaping global oncology drugs industry
CHAPTER 4. GLOBAL MACROECONOMIC OVERVIEW
Figure 4.1: Global GDP growth rate trend
Figure 4.2: Global inflation rate trend
Figure 4.3: Global population growth rate trend
Figure 4.4: Global unemployment rate trend
Figure 4.5: Regional GDP growth rate trend
Figure 4.6: Regional inflation rate trend
Figure 4.7: Regional population growth rate trend
Figure 4.8: Regional unemployment rate trend
CHAPTER 5. INDUSTRY TRENDS
Figure 5.1: Global oncology drugs industry annual trend 2007-12 (US $B)
Figure 5.2: Global oncology drugs industry regional trend 2007-12 (US $B)
Figure 5.3: Global oncology drugs industry regional trend 2007-12 (%)
Figure 5.4: Global oncology drugs industry segment trend 2007-12 (US $B)
Figure 5.5: Global oncology drugs industry segment trend 2007-12 (%)
Figure 5.6: Global oncology drugs industry quarterly trend 2010-11 (US $B)
Figure 5.7: Global oncology drugs industry profitability trend 2007-12
Figure 5.8: Global oncology drugs industry revenue per employee trend 2007-12
Figure 5.9: Cost structure of global oncology drugs industry 2007-12
Figure 5.10: Cost structure in North American oncology drugs industry 2007-12
Figure 5.11: Cost structure in European oncology drugs industry 2007-12
Figure 5.12: Cost structure in Asia Pacific oncology drugs industry 2007-12
Figure 5.13: Top 5 companies vs. oncology drugs industry gross profit & net profit analysis 2012
Figure 5.14: Cash on hand for global oncology drugs industry 2007-12 (US $B)
Figure 5.15: Cash on hand for global oncology drugs industry 2007-12 (%)
Figure 5.16: Asset for global oncology drugs industry 2007-12 (US $B)
Figure 5.17: Assets for global oncology drugs industry 2007-12 (%)
Figure 5.18: Debt for global oncology drugs industry 2007-12 (US $B)
Figure 5.19: Debt for global oncology drugs industry 2007-12 (%)
Figure 5.20: Industry shares of top players in global oncology drugs industry in 2007
Figure 5.21: Industry shares of top players in global oncology drugs industry in 2012
Figure 5.22: Global oncology drugs industry 2007 market share analysis
Figure 5.23: Global oncology drugs industry 2012 market share analysis
CHAPTER 6. INDUSTRY FORECASTS
Figure 6.1: Global oncology drugs industry annual forecast 2013-18 (US $B)
Figure 6.2: Global oncology drugs industry quarterly forecast 2013-14 (US $B)
Figure 6.3: Global GDP growth rate forecast
Figure 6.4: Global inflation rate forecast
Figure 6.5: Global population growth rate forecast
Figure 6.6: Global unemployment rate forecast
Figure 6.7: Regional GDP growth rate forecast
Figure 6.8: Regional inflation rate forecast
Figure 6.9: Regional population growth rate forecast
Figure 6.10: Regional unemployment rate forecast
Figure 6.11: Global oncology drugs industry regional forecast 2013-18 (US $B)
Figure 6.12: Global oncology drugs industry regional forecast 2013-18 (%)
Figure 6.13: Global oncology drugs industry segment forecast 2013-18 (US $B)
Figure 6.14: Global oncology drugs industry segment forecast 2013-18 (%)
CHAPTER 7. EMERGING TRENDS
Figure 7.1: Global oncology drugs industry opportunity by region
Figure 7.2: Global oncology drugs industry opportunity by segment
LIST OF TABLES
CHAPTER 3. INDUSTRY OVERVIEW
Table 3.1: Industry parameters of global oncology drugs industry
Table 3.2: Relative industry attractiveness by region
CHAPTER 5. INDUSTRY TRENDS
Table 5.1: Regional revenue growth rate
Table 5.2: Segment revenue growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total asset
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by revenue growth
Table 5.8: Key companies by revenue decline
CHAPTER 6. INDUSTRY FORECASTS
Table 6.1: Global oncology drugs regional forecast growth rate
Table 6.2: Global oncology drugs segment forecast growth rate
CHAPTER 3. INDUSTRY OVERVIEW
Table 3.1: Industry parameters of global oncology drugs industry
Table 3.2: Relative industry attractiveness by region
CHAPTER 5. INDUSTRY TRENDS
Table 5.1: Regional revenue growth rate
Table 5.2: Segment revenue growth rate
Table 5.3: Percentage change in cost structure
Table 5.4: Percentage change in cash on hand
Table 5.5: Percentage change in total asset
Table 5.6: Percentage change in total debt
Table 5.7: Key companies by revenue growth
Table 5.8: Key companies by revenue decline
CHAPTER 6. INDUSTRY FORECASTS
Table 6.1: Global oncology drugs regional forecast growth rate
Table 6.2: Global oncology drugs segment forecast growth rate
